Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + Cobimetinib + Eribulin (ACE) or Atezolizumab + Eribulin (AE) in Recurrent/Metastatic Inflammatory Breast Cancer
NCT03202316Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2017
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab and cobimetinib in inflammatory breast cancer (IBC) (2 cohorts), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Overall Response Rate up to 2 years. Started Aug 2017; status: active, not recruiting.
02
Drugs
atezolizumabcobimetinib
03
Conditions
inflammatory breast cancer (IBC)
Beyond the preview
Go deeper on NCT03202316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03202316.